肝病中骨质疏松症的评估与管理

Evaluation and management of osteoporosis in liver disease.

作者信息

Hay J Eileen, Guichelaar Maureen M J

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, Southwest, Rochester, MN 55905, USA.

出版信息

Clin Liver Dis. 2005 Nov;9(4):747-66, viii. doi: 10.1016/j.cld.2005.07.003.

DOI:10.1016/j.cld.2005.07.003

PMID:16207574

Abstract

This article discusses the clinical importance of hepatic osteopenia, the identification of risk factors for the individual patient, and the selection of patients, timing, and methods for diagnostic screening. General supportive measures to maximize bone health should be used in all patients at risk. In addition, for the patient with established osteoporosis, specific therapeutic measures may be justified, despite the lack of adequate randomized trials of these agents in patients with hepatic osteopenia.

摘要

本文讨论了肝性骨质减少的临床重要性、个体患者风险因素的识别以及诊断性筛查的患者选择、时机和方法。对于所有有风险的患者，应采取一般支持措施以最大限度地促进骨骼健康。此外，对于已确诊骨质疏松症的患者，尽管缺乏针对肝性骨质减少患者使用这些药物的充分随机试验，但采取特定的治疗措施可能是合理的。